Gal-Dox

Gal-Dox is a **glycoconjugated prodrug of doxorubicin** in which doxorubicin, an anthracycline anticancer agent, is covalently linked to galactose. This modification is designed to utilize the overexpression of asialoglycoprotein receptor 1 (ASGPR1) on certain tumor cells (notably hepatocellular and some breast cancer cell lines), thereby enhancing tumor-selective uptake via receptor-mediated endocytosis. Preclinical studies demonstrate that Gal-Dox shows greater cytotoxicity in ASGPR1-positive tumor cells (such as HepG2 and MCF-7), reduced accumulation and toxicity in normal heart tissue compared to doxorubicin, and improved survival in mouse tumor models. Gal-Dox represents a targeted strategy for tumor-directed therapy, aiming to increase antitumor efficacy while lowering systemic toxicity, particularly cardiotoxicity, relative to standard doxorubicin treatment[2][3].

Other names

Gal-DOXgalactose-doxorubicin conjugategalactosylated doxorubicin